Poster Abstracts 25th

The deadline to submit an abstract for poster presentations has passed.

To inquire about submitting a late abstract please contact



Each poster must be a minimum of 36″ x 48″ and cannot exceed 48″ (vertical) x 96″ (horizontal). Poster board assignments and details on poster set-up will be emailed to presenters in early October.

The Poster Session will be held on Friday, October 26, 2018, from 8:00pm to 10:30pm. Posters will be arranged in alphabetical order by the presenting author’s last name. Copies of the poster on 11″ x 17″ paper can accompany the poster as handouts but cannot be mounted on the poster boards.

For poster presentation inquiries please contact or (310) 570-4705.


Author Abstract Title
Abdulkadir, Sarki Novel Small Molecule MYC inhibitors Suppress Mouse Prostate Cancer and Enhance Immunotherapy
Aggarwal, Rahul A Phase 1b Study of the Oral CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration Resistant Prostate Cancer (mCRPC): a Prostate Cancer Clinical Trials Consortium Study
Al, Abo, Muthana A computational approach to identifying ancestry related alternatively spliced and differentially expressed genes in African American and White prostate cancer
AlDubayan, Saud Novel epidemiological and computational genomic approaches to explore the missing heritability of primary and metastatic prostate cancer
Alyamani, Mohammad HSD3B1(1245A>C) Variant Regulates Dueling Abiraterone Metabolite Effects in Prostate Cancer
Amend, Sarah C1orf116, an unnamed gene of as-yet unknown function, is a putative prostate cancer metastasis suppressor that inhibits the migratory phenotype of would-be metastatic cells
Asangani, Irfan Resistance to BET inhibitor leads to new therapeutic vulnerabilities in castration resistant prostate cancer
Asim, Mohammad A reciprocal feedback between the PDZ-binding kinase and androgen receptor drives prostate cancer
Augello, Michael CHD1 loss modulates distinct AR transcriptional programs to drive prostate tumorigenesis
Axcrona, Karol Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity
Axcrona, Karol Adverse effects after radical prostatectomy are strongly associated with the personality trait of neuroticism
Bakhoum, Samuel Chromosomal instability promotes metastasis through a cytosolic DNA response
Bevan, Charlotte MIR-346 Interaction With Long Non-Coding RNA, NORAD, Reveals a Novel Genome Protection Mechanism And Modulates Response To DNA-Damaging Therapeutics and Immunotherapy in Advanced Prostate Cancer
Borno, Hala Trial Library – a single arm feasibility pilot study to examine the efficacy for a clinical trial online matching website on patient-prompted conversations regarding prostate cancer clinical trials
Bose, Rohit Screens to identify rationale drug combination strategies for advanced prostate cancer
Brennen, Nathaniel Particle Encapsulation of a Prostate-Targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-Resistant Prostate Cancer
Cackowski, Frank Isolation and Analysis of Bone Marrow Disseminated Tumor Cells from Patients with Localized Prostate Cancer
Calais, Jeremie Prospective head-to-head comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in 50 patients with prostate cancer biochemical recurrence after primary prostatectomy: A preliminary analysis
Calais, Jeremie Randomized Phase III Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT]
Campbell, Douglas The biodistribution of Miltuximab® using Gallium-67 nuclear imaging: The MILGa-01 First in Human Trial
Caram, Megan Patient and Provider Variables Associated with Variation in the Systemic Treatment of Advanced Prostate Cancer
Carlo, Maria Mainstreaming germline genetic testing for men with advanced prostate cancer
Castro, Elena PROREPAIR-B: A Prospective Cohort Study of The Impact of Germline DNA Repair Mutations on The Outcomes of Metastatic Castration Resistant Prostate Cancer Patients
Chan, June Obesity and prostate cancer recurrence following radical prostatectomy
Cheng, Michael Microsatellite instability in prostate cancer and response to immune checkpoint blockade
Cherkasov, Artem Small molecule inhibitors targeting AR/AR, AR/ARV and ARV/ARV dimerization interfaces as potential therapies for CRPC
Chu, Gina Cholesterol promotes prostate cancer progression and metastasis
Clarke, Starlynn A Novel CD3xPSMA Bispecific Antibody for Efficient T Cell Mediated Killing of Prostate Tumor Cells with Minimal Cytokine Release
Cooperberg, Matthew When Can Active Surveillance Be Less Active?: Prediction Of Long-term Non-Reclassification for Men With Low-Risk Prostate Cancer
Cotter, Kellie Modulation of Translation Regulation by N6-methyladenosine in Prostate Cancer
Cox, Michael ERG promotes transcriptional reprogramming of prostatic epithelial cells toward a cancer stem cell phenotype
Creighton, Chad Understanding the molecular biology of prostate cancer in the context of other cancers through pan-cancer genomic analyses
Davies, Alastair Combating lineage plasticity to suppress therapeutic resistance in advanced prostate cancer
Denmeade, Samuel Bipolar Androgen Therapy (BAT) for men with Asymptomatic Castrate-Resistant Prostate Cancer: Updated results from the RESTORE study
Dondossola, Eleonora Engineered Bone for Probing Organotypic Growth and Therapy Response of Prostate Cancer Tumoroids in vitro
Drake, Justin Targeting RET Kinase in Neuroendocrine Prostate Cancer
Finn, Stephen Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide
Flavell, Rob Detection of aggressive prostate cancer through pH imaging using hyperpolarized 13C magnetic resonance spectroscopy
Fletcher, Claire MIR-346 Interaction With Long Non-Coding RNA, NORAD, Reveals a Novel Genome Protection Mechanism and Modulates Response To DNA-Damaging Therapeutics in Advanced Prostate Cancer
Garraway, Isla Chromosomal instability (CIN) in diagnostic prostate biopsies predicts prostate cancer metastases
Giri, Veda Provider Knowledge and Practice Needs Regarding Germline Testing for Inherited Prostate Cancer
Goldstein, Andrew Aging is Associated with Changes in the Inflammatory Microenvironment and a Progenitor- Like Luminal Signature in the Mouse Prostate
Gueron, Geraldine Ketone Bodies as a biomarker of the metabolic shift in castration resistance progression: therapeutics implications
Hamid, Anis Compound genomic alterations of TP53, PTEN and RB1 tumor suppressors in localized and metastatic prostate cancer
Hargrove, Amanda Targeting the lncRNAs SChLAP1 and MALAT1 in aggressive prostate cancer
Harmon, Stephanie Spatially discordant uptake within prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT scans
Heaphy, Christopher Among men with higher-grade prostate cancer, Black men are significantly more likely to have greater cancer cell-to-cell variability in telomere length than White men: a clue to racial disparity in prostate cancer outcomes
Hectors, Stefanie Radiomics features measured with multiparametric MRI predict prostate cancer aggressiveness
Henning, Susanne Role of Host GPR120 in Mediating Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
Hofman, Michael Voxel based dosimetry of 177Lu-PSMA-617 within a prospective clinical trial: Whole body tumour dosimetry and correlations with pre-therapeutic imaging and biochemical outcomes
Hope, Thomas Results of the first Phase 3 Trial of 68Ga-PSMA-11 in Biochemical Recurrence
Jamieson, Christina PROTUX Clinical trial: An open label, single institution, pilot study of rituximab neoadjuvant therapy in patients with high risk prostate cancer scheduled to undergo radical prostatectomy
Jarrard, David Metabolic Modulation at The Time of Androgen Deprivation Therapy Improves Prostate Cancer Survival in Patients
Jayaram, Anu Plasma androgen receptor (pAR) status at emergence of metastatic castration-resistant prostate cancer (mCRPC)
Jones, Jennifer Nanoscale Flow Cytometry for EV and Exosome Studies
Jones, Jeremy PPAR Gamma Antagonists as Monotherapy and in Combination with Checkpoint Inhibitors in Prostate Cancer
Joshua, Anthony Final results of a prospective phase 2 pilot trial of 177Lu-PSMA 617 (LuPSMA) in men with castrate resistant metastatic prostate cancer (mCRPC), with correlations to baseline PET results.
Joshua, Anthony Expansion of Tumour-Infiltrating Lymphocytes (TIL) from Prostate Cancer and Adjacent Normal Tissue
Kaldjian, Eric Multi-parameter immunofluorescence assays for detection of androgen receptor, androgen receptor variant 7 and PSMA in prostate circulating tumor cells
Karthaus, Wouter Identifying novel regulators of lineage plasticity in an organoid model of transdifferentiation
Knudsen, Beatrice Digital Pathology and Artificial Intelligence for Prostate Cancer Diagnosis, Grading and Prognostication
Kortylewski, Marcin Dual function of CpG-STAT3 antisense oligonucleotides is essential for the induction of antitumor immunity against genetically distinct castration-resistant prostate cancers
Kothari, Vishal Investigating DNAPK as a therapeutic target and a prognostic biomarker in castration- resistant prostate cancer
Ku, Sheng-Yu Loss of Notch signaling facilitates neuroendocrine differentiation in advanced prostate cancer
Kyriakopoulos, Christos A pilot trial of neoadjuvant chemohormonal therapy with PSMA PET directed dissection of prostatectomy specimens for analysis of the tumor microenvironment
Labbe, David High-fat diet propels prostate cancer by rewiring the metabolome and amplifying the MYC program
Larman, Benjamin Ligation in situ Hybridization (LISH): A Multiplexed Gene Expression Platform for Analysis of FFPE RNA
Leach, Damien The role of the microenvironment in therapeutic response to anti-prostate cancer treatment
Lee, John CUDC-907, a dual PI3K and HDAC inhibitor, reduces AR-FL, AR-Vs, and Myc expression in prostate cancer
Lee, Yongik A PRC2 Independent role of EZH2 in Androgen Receptor Signaling in Prostate Cancer
Li, Hui The Long Noncoding RNA SChLAP1-AS is Associated with Prostate Cancer Progression
Li, Zhenfei Androgen metabolism potential correlates with prostate cancer progression
Linder, Karen Impact of positron emission tomography with 18F-fluciclovine on management of patients with suspected recurrence of prostate cancer: results from the LOCATE trial
Loeb, Stacy Prostate Cancer Journal Club #ProstateJC on Twitter: One-Year Experience
Lorenzin, Francesca Agnostic mutual exclusivity analysis for synthetic lethal pair identification
Lotan, Tamara RESPOND: A National Study of Prostate Cancer in African Americans
Madan, Ravi Intermittent Short Course Enzalutamide in Biochemically Recurrent Prostate Cancer
Mahajan, Nupam Targeting Androgen Receptor and ACK1 signaling with Novel Epigenetic Therapeutics in Enzalutamide-resistant Castration-Resistant Prostate Cancer
Makarov, Danil Designing a Theory-Based Intervention to Improve the Guideline-Concordant Use of Imaging to Stage Incident Prostate Cancer
Malek, Reem Linking EMT to DNA damage response and PARPi resistance in prostate cancer
Malihi, Paymaneh Clonal Diversity Revealed By Morphoproteomic And Copy Number Profiles Of Single Prostate Cancer Cells At Diagnosis
Markowski, Mark COncurrent adMinistration of Bipolar Androgen Therapy and nivolumab in men with metastatic Castration-Resistant Prostate Cancer [COMBAT-CRPC]
Mateo, Joaquin Genomics of prostate primary tumor biopsies identify aberrations associating with aggressive disease and those emerging during treatment
Maxwell, Kara Implication of Gleason score for the precision medicine treatment of patients with localized prostate cancer
McArt, Darragh Integrative Analytics and Artificial Intelligence
McBride, Sean ARN-509 (apalutamide) + Abiraterone acetate + Leuprolide with Stereotactic, Ultra- Hypofractionated Radiation (AASUR) in Very High-Risk Prostate Cancer
McKay, Rana Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP)
McNamara, Megan Race-Related Germline Polymorphisms in Key Androgen Transport Genes Among Black (B) and White (W) Men with Metastatic Castrate Resistant Prostate Cancer (mCRPC) Treated with Abiraterone Acetate plus Prednisone: Single Nucleotide Polymorphism Analyses from the Abi Race Trial
Mehra, Niven In-depth assessment of metastatic castration-resistant prostate cancer with a high tumour mutational burden
Mitrofanova, Antonina Predictive modeling of response to androgen-deprivation in prostate cancer
Miyamoto, David RNA-Based Circulating Tumor Cell Signatures for Localized Prostate Cancer
Montie, Heather Androgen receptor acetylation modulates proliferation of castrate-resistant prostate cancer
Moran, Amy Heterogenous activation of immune suppressive pathways revealed by scRNAseq may underscore resistance to PD-1 therapy in metastatic castration resistant prostate cancer
Morrissey, Colm Defining the molecular phenotypes of metastatic castration-resistant prostate cancer and their sensitivity to FGF pathway inhibition
Mouw, Kent Developing Preclinical Models to Study DNA Repair Deficiency in Prostate Cancer
Mu, Ping Identifying Novel Gene Deletions as Predicting Biomarkers of Antiandrogen Resistance in Advanced Prostate Cancer
Narayan, Vivek Phase 1 Clinical Trial of PSMA-directed/TGFβ-insensitive CAR-T cells in Metastatic Castration-Resistant Prostate Cancer: Safety, Correlative Studies, and Future Directions following Preliminary Dose Escalation
Navone, Nora FGFR1/FGFR1 isoforms accelerate prostate cancer progression to metastasis
Neklesa, Taavi ARV-110: an oral androgen receptor PROTAC degrader for prostate cancer
Nevalainen, Marja Positive STAT5 protein and locus amplification status predicts prostate cancer recurrence after radical prostatectomy to assist precision medicine of prostate cancer
Nevalainen, Marja STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation Through Inhibition of RAD51 and DNA Repair
Nickols, Nicholas Potential impact of 68Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning
Niknafs, Yashar The Landscape of Long Non-Coding RNAs in Metastatic Prostate Cancer
Njar, Vincent Development of Next Generation Galeterone Analogs (NGGAs) for Prostate Cancer Therapy
Oh, David Single cell discrimination of immunotherapy-induced changes in the prostate tumor microenvironment
Pachynski, Russell Profiling immune cell trafficking within the prostate tumor microenvironment
Park, Jung, Wook Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage
Parkes, Eileen Identification of a high risk, immune-active subgroup of primary prostate cancer
Patierno, Steven Targeting RNA Splicing in Race-Related Aggressive and Lethal Prostate Cancer
Pearson, Helen Interrogating how PIK3CA oncogenic mutation contributes to prostate cancer
Perez-Lopez, Raquel Towards clinical qualification of whole-body diffusion-weighted MRI in patients with metastatic castration resistant prostate carcinoma with bone metastases
Pitchiaya, Sethu Unraveling molecular heterogeneities in advanced prostate cancer at single cell resolution
Preston, Mark Risk prediction of aggressive prostate cancer using baseline PSA during midlife and inherited genetic variants in Caucasian men
Puca, Loredana Rovalpituzumab tesirine as a therapeutic agent for neuroendocrine prostate cancer
Qiao, Yuanyuan Development of a Novel Autophagy Inducing Multi-Kinase Inhibitor for the Treatment of Castration Resistant Prostate Cancer
Quigley, David Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
Reder, Nicholas 3D molecular pathology with open-top light-sheet microscopy
Reichert, Zachery Non-invasive interrogation of oligometastatic castration-resistant prostate cancer and the benefit of metastasis directed therapy in the phase II FORCE randomized clinical trial
Rickman, David N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer
Rodriguez-Bravo, Veronica Nuclear pore composition contributes to prostate cancer progression
Russo, Joshua DPP4 and HER2-Mediated Mechanisms of Resistance to Androgen Deprivation Therapies in Advanced Castration-Resistant Prostate Cancer (CRPC)
Salami, Simpa Molecular Dissection of Magnetic Resonance Imaging Visible and Invisible Prostate Cancer
Schiewer, Matthew PARP-1 regulates DNA repair factor availability
Selth, Luke A miR-194-regulated transcriptional network is associated with progression to androgen receptor-independent prostate cancer
Shafi, Ayesha Patient Derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response
Shalapour, Shabnam Platinoid-chemotherapy upregulation of MHC-I machinery in tumor cells determines the response to checkpoint inhibitors
Sharp, Adam Measurement Science of the Androgen Receptor Splice Variant-7 (AR-V7) Protein in Primary and Castration Resistant Prostate Cancer (CRPC) Tissue
Simmons, Andrew Genomic profiling of circulating tumor DNA (ctDNA) and tumor tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)
Smith, Bryan Pan cancer analysis uncovers a molecular link between human adult stem cells and aggressive small cell neuroendocrine cancers from different tissues
Smith, Jenessa PSMA-specific CAR T-Stem Cell Memory Therapy Shows Potent anti-Tumor Effects in Solid Tumor Prostate Cancer Models
Stopsack, Konrad Low expression of the androgen-induced tumor suppressor PLZF in lethal prostate cancer
Takeda, David A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer
Tien, Jean Epigenetic reprogramming with antisense oligonucleotides enhances the effectiveness of androgen receptor inhibition in castration-resistant prostate cancer
Traka, Maria Transcriptional changes in prostate of men on active surveillance following a 12-month glucoraphanin-rich broccoli intervention – results from the ESCAPE study
Tsai, Hung-Ji Targeting karyotypic heterogeneity in aneuploid populations
Vaishampayan, Ulka Randomized trial of enzalutamide (Arm A) versus bicalutamide (Arm B) in combination with androgen deprivation (ADT) in metastatic hormone sensitive prostate cancer (mHSPC): A Prostate Cancer Clinical Trials Consortium Trial
Vander Griend, Donald MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease
VanderWeele, David Organoid culture screen for therapies targeting aggressive variant prostate cancer
Viswanathan, Srinivas Structural alterations in castration-resistant prostate cancer revealed by linked-read genome sequencing
Viswanathan, Vasanthi Targeting the androgen-indifferent state of prostate cancer through ferroptosis induction
Walsh, Bradley Better differentiating aggressive from non-aggressive prostate cancer using MiCheck®
Wilkinson, Scott Genetic features predictive of response to anti-androgen therapies in aggressive prostate cancer
Williams, Anthony SOX2 is an AR Repressed Gene That Drives Castration-Resistant Prostate Cancer Progression and Mediates AR-Targeted Therapeutic Resistance
Wise, David Increased Dickkopf-1 (DKK1) is a feature of metastatic non-neuroendocrine castration- resistant prostate cancer with low PSA
Wyatt, Alexander Circulating tumour DNA prior to therapy initiation in de novo metastatic prostate cancer
Yang, Lu IL-8 prevent prostate cells from oxidative stress induced by GSK-3beta through active the mTOR signaling pass-way
Yang, Rendong Indel detection from DNA and RNA sequencing of primary and advanced prostate cancer
Ye, Huihui DNA Mismatch Repair Protein Deficiency (MMRD) and Programmed Cell Death Ligand-1 (PD-L1) Expression in Metastatic and High-Risk Localized Prostate Cancer
Yuan, Xin Wnt Signaling Targets in ADT Resistant CRPC
Zarif, Jelani Mannose Receptor positive macrophage infiltrate correlates with prostate cancer onset and metastatic castration-resistant disease
Zhao, Di CHD1 Contributes to Prostate Cancer Development and Progression Through Cell-Intrinsic and -Extrinsic Mechanism
Zhao, Shuang Novel transcriptomic signature for predicting functional RB1-loss with clinical implications in localized and metastatic castration resistant prostate cancer
Zhu, Yezi High-resolution survey of the AR variant expression landscape in metastatic castration-resistant prostate cancer